Navigation Links
Misonix Announces New Distribution Agreement for Israel
Date:2/20/2009

FARMINGDALE, N.Y., Feb. 20 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has entered into a new, three year, exclusive distribution agreement with privately-held LAVI Industrial & Medical Agencies Ltd., based in Kfar Saba, Israel, for the distribution of the SonaStar(TM) Ultrasonic Surgical Aspirator and the BoneScalpel(TM) Ultrasonic Bone Cutter.

The agreement provides LAVI with the rights to sell in Israel and includes minimum purchase requirements.

LAVI's medical business has experienced steady sales growth for several years and has built a reputation as a distributor of state-of-the-art medical devices and capital equipment, with special emphasis in neurosurgery and spine surgery.

The SonaStar is used by Neuro and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels. In addition, OsteoSculpt(TM) bone shaving technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument without the potential hazards associated with rotary sharps.

"Misonix is very excited about LAVI joining our sales and distribution organization. We know LAVI as a premier distributor of advanced medical equipment in Israel," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "We are particularly pleased that they will be distributing two of our product platforms through their well established channels."

About Misonix:

Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

    Investor Relations Contact:
    Cameron Associates, Inc.
    Kevin McGrath
    212-245-4577
    Kevin@cameronassoc.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Misonix Reports Earnings and Increased Revenues for the Three and Six Months Ended December 31, 2008
2. Misonix Schedules Second Quarter Fiscal Year 2009 Financial Results Conference Call; February 9, 2009 at 4:30 P.M. Eastern
3. Misonix Announces New HIFU Distribution Agreement for Italy
4. Misonix Announces Extension and Expansion of Distribution Agreement With Mentor Corporation
5. Misonix Reports First Quarter Fiscal Year 2009 Financial Results
6. Misonix Schedules First Quarter Fiscal Year 2009 Financial Results Conference Call; November 13, 2008 at 4:30 P.M. Eastern
7. Misonix Subsidiary, Sonora Medical Systems, Announces a Major Ultrasound Probe Study
8. Misonix To Present at The Rodman & Renshaw 10th Annual Healthcare Conference
9. UPDATE: P&M Corporate Finance Announces Partnership with Robin Young to Present the Fifth Annual Spine Technology Summit
10. Volcano Corporation Announces Webcast of February 25th Analyst Day
11. XTENT Announces Fourth Quarter 2008 Financial Results and Business Progress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... Facial plastic surgeon, Dr. John D. Rachel ... a portion of proceeds to two local organizations: North Chicago Animal Control and Friends ... is a team of authorized and trained volunteers who support rescued animals held ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... "ProBrand Flip ... and all media," said Christina Austin - CEO of Pixel Film Studios. , ProBrand ... easy to use drop zones. Editors can select from a variety of flip book ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Tomorrow Trump Goes To Washington”: a ... to the presidency and to America. “Tomorrow Trump Goes To Washington” is the creation ... she can for this country. , Nancy attributes her patriotic nature to her WWII ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... to present at the International Probiotic Association’s Washington DC workshop on November 2nd. ... to engage in dialog regarding probiotic dietary supplement regulations. , Dr. Leyer ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... because of a higher risk of serious health problems, such as cardiovascular illness, ... Dr. Peiman Soleymani of Beverly Hills Periodontics & Dental Implant Center notes that ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... WESTLAKE VILLAGE, Calif. , Dec. 6, ... a privately held, clinical-stage medical dermatology and ... Creabilis plc, a privately held specialty pharmaceutical ... for common inflammatory skin conditions, including psoriasis, ... terms of the agreement, Sienna will make ...
(Date:12/6/2016)... Calif. , Dec. 6, 2016  Regulus ... biopharmaceutical company leading the discovery and development of ... drug development candidates at its R&D day, held ... first candidate, RGLS5040, is an anti-miR targeting microRNA-27 ... second candidate, RGLS4326, is an anti-miR targeting microRNA-17 ...
(Date:12/6/2016)... - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: ... in the use of cannabinoids for the treatment ... 2015 InMed initiated its COPD program using its ... potential active compounds that can be useful for ... assays using human lung fibroblasts (HFL-1 cell line), ...
Breaking Medicine Technology: